News | April 25, 2024
Devyser receives IVDR approval for post-transplant monitoring software
Find out more
All articles
Devyser receives MDSAP certification for Brazil
Devyser publishes annual report for 2023
Devyser´s annual report 2023 has today been published on the company´s website. The report is...
Devyser CFTR 68 provides NHS Scotland with trustworthy, rapid results
We spoke with Dr. Andrew Purvis, Clinical Scientist for West of Scotland Centre for Genomic...
Devyser achieves breakthrough in the US with cystic fibrosis NGS test
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is...
2023: A year in studies
2023 was an excellent year for Devyser, and a range of our products appeared in scientific journals...
Devyser announces study publication demonstrating dd-cfDNA detection in dual donor kidney transplant patients
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...
Devyser Diagnostics AB publishes year-end report for January to December 2023
“Devyser is able to report strong sales growth and record high gross margins for the fourth...
Devyser Accept cfDNA demonstrates high performance in newly published peer-reviewed article
Devyser strengthens its management team
Top performance at high-throughput: Devyser RHD maintains high sensitivity within an automated, high-throughput setting in Sahlgrenska University Hospital Study
Over the past decade, there has been a wealth of research investigating the ideal approach to RHD...
Devyser Genomic Laboratories signs first commercial agreement
Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first...